Technical Analysis for OCUL - Ocular Therapeutix, Inc.

Grade Last Price % Change Price Change
grade D 4.06 0.25% 0.01
OCUL closed up 0.25 percent on Monday, March 18, 2019, on approximately normal volume. It was able to find support at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical OCUL trend table...

Date Alert Name Type % Chg
Mar 18 50 DMA Support Bullish 0.00%
Mar 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 18 Doji - Bullish? Reversal 0.00%
Mar 18 Stochastic Reached Oversold Weakness 0.00%
Mar 18 Wide Bands Range Expansion 0.00%
Mar 18 Oversold Stochastic Weakness 0.00%
Mar 15 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.25%
Mar 15 Inside Day Range Contraction 0.25%
Mar 15 Wide Bands Range Expansion 0.25%
Mar 15 Down 3 Days in a Row Weakness 0.25%

Older signals for OCUL ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Ocular Therapeutix, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapies based on its proprietary hydrogel platform technology for treating eye diseases and conditions. The company offers ReSure Sealant, a topical liquid hydrogel that creates a sealant to prevent post-surgical leakage from clear corneal incisions made during cataract surgery Its lead product candidates comprise OTX-DP, which is in Phase III clinical trials for the treatment of post-surgical ocular inflammation and pain; and OTX-TP that is in Phase II clinical trials for the treatment of glaucoma and ocular hypertension. The company's earlier stage product candidates include OTX-DP, which is in Phase II clinical trials for the treatment of allergic conjunctivitis; OTX-MP that has completed Phase I clinical trials for the treatment of bacterial conjunctivitis; and Anti-VEGF hydrogel depot, which is in preclinical testing for the treatment of wet AMD. Ocular Therapeutix, Inc. sells its ReSure Sealant through a network of independent medical device distributors in the United States. The company was founded in 2006 and is headquartered in Bedford, Massachusetts.
Health Medical Specialties Pain Clinical Trial Glaucoma Cataract Treatment Of Glaucoma Eye Diseases Incisions Allergic Conjunctivitis Allergology Cataract Surgery Ocular Hypertension Post Surgical Ocular Inflammation
Is OCUL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 8.28
52 Week Low 3.465
Average Volume 494,586
200-Day Moving Average 5.5766
50-Day Moving Average 4.015
20-Day Moving Average 4.2905
10-Day Moving Average 4.269
Average True Range 0.2833
ADX 22.98
+DI 14.8652
-DI 26.5469
Chandelier Exit (Long, 3 ATRs ) 4.1501
Chandelier Exit (Short, 3 ATRs ) 4.4199
Upper Bollinger Band 4.9635
Lower Bollinger Band 3.6175
Percent B (%b) 0.33
BandWidth 31.371635
MACD Line 0.035
MACD Signal Line 0.0878
MACD Histogram -0.0528
Fundamentals Value
Market Cap 117.97 Million
Num Shares 29.1 Million
EPS -2.15
Price-to-Earnings (P/E) Ratio -1.89
Price-to-Sales 88.04
Price-to-Book 3.48
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.32
Resistance 3 (R3) 4.31 4.22 4.27
Resistance 2 (R2) 4.22 4.16 4.22 4.26
Resistance 1 (R1) 4.14 4.11 4.10 4.15 4.24
Pivot Point 4.05 4.05 4.03 4.05 4.05
Support 1 (S1) 3.97 3.99 3.93 3.98 3.88
Support 2 (S2) 3.88 3.94 3.88 3.86
Support 3 (S3) 3.80 3.88 3.85
Support 4 (S4) 3.81